Human ribonuclease inhibitor (hRI) is an acid protein with a molecular weight of 50 kDa. It can inhibit the activity of pancreatic RNase (RNase A). Angiogenin (Ang) is a member of the ribonuclease super family. It has 35% identity with RNase A and contains ribonucleolytic activity. The substrate specificity of angiogenin seems, however, to be more restricted than that of the pancreatic RNase. Since Ang is an important angiogenic factor and RI is a highly efficient inhibitor of Ang, it can be hypothesized that RI may be a latent antiangiogenic drug. This study focuses on the feasibility of transfecting the ri gene into mice hematopoietic cells and inducing the expression of the ri gene to block the angiogenesis of solid tumors. First, the cDNA gene of the ri from human placenta was cloned and inserted in a retroviral vector, pLNCX. The combined vector pLNCX-ri was transfected into retroviral packaging cells, PA317, and a clone producing a high titer of virus was obtained. Next, isolated hematopoietic cells from mice bone marrow were infected with viruses carrying the pLNCX-ri. The infected cells were then injected into lethally irradiated mice. The expression and the contribution of RI were assayed in vivo. After administration of hematopoietic cells carrying the ri gene, mice were implanted with B16 melanomas for 21 days. The results showed that tumors of control groups became large and well vascularized. In contrast, tumors from mice groups treated with hematopoietic cells carrying the ri gene were small and possessed a relatively low density of blood vessels. The inhibited growth rate of the tumors was 47%. This study demonstrated the potential utility of gene therapy for systemic delivery of a novel antiangiogenic agent -hRI.
W
ith the hypothesis that solid tumor growth is angiogenesis dependent, comes the realization that angiogenesis itself might be a potential therapeutic target. 1 This fundamental principle states that tumor growth beyond a few mm 3 in size strictly depends on the formation of new blood vessels. 2 Recent studies showed a direct correlation between the density of tumor vessels and an adverse prognosis in patients with a variety of solid tumors, including breast, colon, lung, kidney, bladder, and head and neck tumors. [3] [4] [5] Considering the importance of vascularization in tumor progression, angiogenesis inhibition may, therefore, represent a potentially powerful new approach to cancer therapy.
Angiogenic factors, such as angiogenin (Ang), 6 fibroblast growth factor (FGF) 7 and vascular endothelial growth factor (VEGF), 8, 9 have been demonstrated to play very important roles in angiogenesis. Ang was originally purified from human tumor cell conditioned medium, and later from human plasma on the basis of its capacity to induce neovascularization. As little as 0.5 ng Ang can induce blood vessel formation on the CAM. It is also a member of the pancreatic ribonuclease superfamily that has unusual biological properties. Human ribonuclease inhibitor (hRI) and Ang form an exceedingly tight 1:1 complex 10 resulting in blockage of Ang activity. Gene therapy has also been utilized to inhibit cancer angiogensis. [11] [12] [13] [14] Compared with protein therapy, there are several potential advantages. As a prelude to the potential clinical application of RI gene therapy, we cloned the human ri gene and inserted it in a retroviral vector pLNCX. The vector was packaged into PA317 cells. Collected viruses were used to infect mouse bone marrow hematopoietic cells. The gene-modified cells demonstrated antitumor activity by inhibition of tumor angiogenesis in vivo.
Materials and methods

Cloning and plasmid construction
The pET23b plasmid containing human RI cDNA was constructed by our group. 15 A 1.4 kb NdeI/XhoI fragment of pET23b containing the entire RI sequence was subcloned into the HpaI site of the pLNCX retrovival vector (Invitrogen). Plasmids were amplified in DH5a and purified by the alkaline lysis method.
Generation and determination of titer of packaging cell
The retroviral packaging cell line PA317 was obtained from the Tianjin Hematology Institute of China. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM), with 10% FBS supplement at 371C with 5% CO 2 . The cells were transfected using the LipofectA-MINE reagent purchased from Invitrogen. A measure of 2 mg of pLNCX-ri construct was mixed with 15 ml lipofectAMINE. The complexes were diluted with 0.8 ml serum-free DMEM and were added onto PBS-rinsed PA317 cells. The cells were incubated at 371C with 5% CO 2 for 10 hours and then the medium was replaced with the complete medium. Transfected cells were selected in the presence of 800 mg/ml G418 (GIBCO) for 2 weeks. Resistant colonies were isolated and amplified. Empty vector pLNCX was used as a control. NIH-3T3 TK À cells were used to titer the two retroviral vectors. The supernatant of each clone was harvested and filtered through a 0.45 mm filter after 48 hours incubation. The supernatants were diluted with serum-free medium at 10-fold serial dilutions. NIH-3T3 TK À cells were seeded at 1 Â 10 5 cells/well in a six-well plate and grown to 50% confluency. The plate was replaced with the diluted viruscontaining medium supplemented with 8 mg/ml polybrene (Sigma). After 1 hour incubation, complete DMEM medium was added to dilute polybrene to 2 mg/ml. Cells were then incubated for an additional 36 hours after which, the plate was refilled with medium containing 800 mg/ml G418. On day 8, colonies were stained with methylene blue and the vector titer was calculated as the number of colony forming units (CFU) per ml. 16 Infection of bone marrow hematopoietic cells Donor mice (C57/BL males, 8-12 weeks) were treated with 150 mg of 5-fluorouracil per kg of body weight 5 days prior to marrow harvest. Bone marrow was harvested from femurs. After Ficoll Hypaque (Pharmacia) gradient separation, mononuclear cells were prestimulated with IL-3 þ IL-6 þ SCF (50 ng/ml each) for 1 day and infected with cell-free retroviral supernatants in the presence of 8 mg/ml polybrene, 15% FBS, and 15% horse serum. The same growth factors were also added throughout the culture. The infection process was repeated thrice every 12 hour . After infection, cells were washed twice in phosphate-buffered saline (PBS) and used for animal studies or plated in semisolid agar medium for the infection efficiency assay.
Assay for infection efficiency
Infected hematopoietic colonies were identified using the CFU method. Briefly, colonies growing in agar were amplified and used to prepare high molecular weight DNA for PCR analysis. A pair of primers were used to amplify a part of the vector sequence and a part of the ri sequence. The following primers were used: 5 0 CCA AGC TTG TTT ATG AGC CTG GA 3 0 and 5 0 GCC GAG AGG CTG CAA TAC T 3 0 . Each sample was amplified for 35 cycles (941C for 30 s to denature the DNA, 551C for 30 s for primer annealing, and 721C for 1 minute for primer extension) resulting in a 479-bp product. A volume of 10 ml of reaction mixture was electrophoresed on a 2% agarose gel. The infection efficiency was regarded as the percentage of positive PCR product.
Immunofluorescent analysis for transgene expression
Infected bone marrow cells were fixed on coverslips in 80% acetone for 10 minutes, carefully washed twice in PBS and incubated in 0.5% Triton X-100 at 371C for 2 Â 5 minutes. Coverslips were then carefully washed twice in PBS and treated with 3% bovine serum albumin (BSA) in PBS for 20 minutes at 371C to block nonspecific staining. Coverslips were incubated in the rabbit antihuman RI polyclonal antibody (prepared by our group) (1:300) dilution in PBS containing 3% BSA at 371C for 2 hour. After rinsing three times with 3% BSA in PBS for 3 Â 5 minutes, the cells were incubated in goat anti-rabbit Ig-FITC (1:100) for 30 minutes at 371C. Coverslips were washed thoroughly with PBS, and finally sealed with glycerin. Observations were performed using Olympus immunofluorescence and light microscope.
Western blot determination of transgene expression
Stable empty vector and recombinant vector-infected colonies were amplified 5 Â 10 7 , cells were harvested and washed three times with PBS, and boiled in 100 ml of SDS/ PAGE sample buffer. Samples of bone marrow, spleen and liver were homogenized and boiled in SDS/PAGE sample buffer. Boiled samples were electrophoresed on a 10% SDS/PAGE gel and transferred to a nitrocellulose membrane. After blocking with 3% BSA in PBS overnight at 41C, the membrane was probed with the primary antibody rabbit anti-human RI IgG (1:200) (prepared by our group) for 1hour at 371C. The membrane was washed thoroughly for 3 Â 10 minutes with TBST and then incubated with horseradish peroxidase-conjugate secondary antibody goat anti-rabbit IgG (1:500). Proteins were detected by a peroxidase color reaction using DAB as substrate.
RT-PCR analysis
RNA was extracted from animal's bone marrow cells, spleen, thymus, and liver using the Trizol reagent (Invitrogen). The following primers were used: 5 0 CCA AGC TTG TTT ATG AGC CTG GA 3 0 and 5 0 GCC GAG AGG CTG CAA TAC T 3 0 , resulting in a 479-bp product. RT-PCR was carried out in a reaction volume of 50 ml (5 ml 5 Â buffer, 5 U Taq, 1 ml each primer, 1 mg RNA). RT-PCR proceeded with the following parameters: 501C for 30 minutes, 941C for 2 minutes for RT reaction, then 941C for 30 s, 551C for 30 s and 721C for 1.5 minutes for 30 cycles for PCR. The PCR products were loaded onto a 2% agarose gel, and stained with ethidium bromide.
Animal studies
The infected bone marrow cells described above were maintained in the presence of 800 mg/ml G418 for 5 days to kill uninfected cells. In all, 80 female C57BL mice were divided into four groups: untransplanted group, uninfected group, empty vector group, and the ri infected group. All animals received 10 Gy X-ray 1 day prior to bone marrow transplantation. Bone marrow transplantation of 3.7 Â 10 7 cells per kg of body weight was performed in the last three groups. The uninfected group received untreated bone marrow cells, the empty vector group received empty vector-infected bone marrow cells and the ri-infected group received ri gene containing vector-infected bone marrow cells. After 7 days post bone marrow transplantation, a murine melanoma cell line B16 was implanted into the left flank of the four mice groups (5 Â 10 5 cells/mouse in 100 ml of PBS). After the development of an easily palpable tumor (10-12 days, approximately 5 mm in diameter), tumor size was then measured using a caliper every other day. Tumor volume was calculated by using the following formula: tumor volume ¼ 1 2 (width) 2 Â length. Tumor tissues were fixed in formalin and pathology analysis for vessel density was performed. Immunohistochemical assays were performed to further confirm the impact of RI on angiogenesis. The antigen-retrieving steps were taken by means of boiling in the citrate buffer for 15 minutes at 92-981C and trypsinizing with 1.25 g/l for 15 minutes at 371C, tissue sections were incubated for 90 minutes in polyclonal primary antibody of factor VIII-related antigen(1:50) at 371C, the sections were incubated in goat anti-rabbit secondary antibodies(IgG/Bio) for 15 minutes at 371C, using SP (streptavidin/peroxidase) Histostaint-Plus Kits, DAB staining. The nuclei were counterstained by hematoxylin. The rest of the procedure was performed according to the manufacturer's instruction. Tumor tissues were also used for flow cytometery for the analysis of apoptosis. Meanwhile, bone marrow cells, spleen, thymus, and liver were removed from mice for detection of the expression of the ri gene by Western blot, RT-PCR, PCR, and immunfluorecence.
Statistics
All data are presented as the mean7SD. The comparison among the control groups and ri-treated group was evaluated using Student's t-test. P-value less than 0.05 was considered significant. All statistical analyses were performed using the SPSS 10.0 for Windows software.
Results
Generation and determination of titer of packaging cell
The human ri gene was cloned into a retroviral vector, pLNCX, and a recombinant expressing vector pLNCX-ri was generated, with the ri gene under the control of a murine cytomegalovirus (CMV) promoter (see Fig 1) . After transfection of pLNCX and pLNCX-ri vector into the packaging cell PA317, 18, and 20 G418-resistant colonies were obtained, respectively. To determine the titers of these colonies, we used NIH-3T3 TK À cells. The highest titer of pLNCX-and pLNCX-ri-producing cells was 6 Â 10 4 and 2.5 Â 10 5 cfu/ml, respectively.
Infection efficiency analysis
To assess the infection efficiency of retrovirus into bone marrow hematopoietic cells, mononuclear cells were first prestimulated with IL-3 þ IL-6 þ SCF (50 ng/ml each) for 1 day to increase infection efficiency. Mononuclear cells were then infected with virus-containing medium thrice every 12 hour. Since the half-life of retrovirus is 6 hours, 12-hours-time was chosen for the infection process. The 10 colonies grown on 0.33% semisolid medium were amplified and subjected to PCR analysis. The 479-bp specific product was amplified in four colonies among the selected 10 colonies (see Fig 2) , indicating an infection efficiency of 40%. In all, 10 cell colonies grown on semisolid medium were selected randomly and subjected to PCR reaction. A pair of primers were used to amplify a 479-bp band including a small part of vector sequences and the 5 0 end of ri gene (see Fig 1) . The infection efficiency is regarded as the percentage of positive PCR product. The result showed four positive bands from 10 samples, so the infection efficiency was 40%.
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Microscope and immunofluorescent analysis for transgene expression
To confirm that ri gene had indeed been distributed to hematopoietic cells, microscope and immunofluorescent staining of cells infected with empty vector virus or recombinant virus were performed. As shown in Figure 3 , the ri gene was efficiently expressed in infected cells, while empty virus-infected cells showed no expression, indicating that retrovirus vector could infect hematopoietic cells well and the ri gene could be expressed efficiently. In Anti-tumor effect of RI gene therapy P Fu et al animal studies, immunofluorescent staining was used to detect ri expression in bone marrow and peripheral blood.
Western blot determination of transgene expression
To determine the expression of the ri gene, several empty vector virus and recombinant virus-infected colonies were selected and amplified. As expected, the ri gene was expressed in hematopoietic cells efficiently, while empty vector virus-infected cells showed a slight positive protein band because of nonspecific binding. In animal studies, to assess ri expression in different tissues, protein samples from bone marrow, spleen, and liver were electrophoresed. The ri gene was expressed in all tissues; however, it was expressed most efficiently in bone marrow and liver tissues (Fig 4) .
RT-PCR analysis
In an attempt to confirm the distribution of the ri gene in different tissues, RT-PCR was performed with samples from bone marrow, spleen, thymus and liver. The results showed different expression efficiencies in the different tissues. Bone marrow samples from all animals in the ri-infected expressed detectable ri gene by RT-PCR. The expression efficiency in spleen tissue was 40%, thymus was 38%, while the lowest in liver was only 20% (shown in Fig 5) .
Animal studies
In order to study whether the ri gene-modified hematopoietic cells can inhibit the growth of primary B16 melanoma, 5 Â 10 5 tumor cells in 100 ml of PBS were implanted into the left flank of C57BL mouse. Tumor size was then measured every other day for 12 days. In this study, ri-modified hematopoetic cells significantly inhibited the growth rate of the melanoma, compared with the other three control groups. At day 21 after tumor cell implantation, tumors in the ri-infected group were 47% smaller than tumors in the other three groups (see Table 1 ). To confirm whether the inhibition was correlated with the inhibition of blood vessel formation in tumor, pathological analysis was performed. Angiogenesis within tumor tissue was estimated counting the number of microvessels on the section. Immunohistochemical assays were carried out to further confirm impact of RI on angiogenesis. The results showed that apparent inhibition of angiogenesis in tumor tissue in mice transfected with RI gene, whereas numerous small vessels can be seen in mice of control groups. Treatment with the ri gene resulted in apparent inhibition of angiogenesis in tumors (see Table 2 , Fig 6) . In addition, the increased apoptotic tumor cells were found within the tumor tissues in mice treated with the ri gene-modified The weight of tumors was measured on day 21 after implantation with B16 melanoma. The treatment with ri gene significantly inhibited the growth of B16, compared with the other control groups.
a ri-infected group versus the other three control groups, Po0.001. The vessel density was determined by counting the number of the microvessels per high-power field in the section. The treatment with ri gene resulted in apparent loss of vessel density than that of the other control groups in the tumor tissues.
a ri-infected group versus the other three control groups, Po0.001. There was no significant difference among the control groups.
bone marrow cells compared with controls (see Fig 7) . There was no significant difference among the control groups (P4.05).
Discussion
Angiogenesis is required for the growth and metastasis of solid tumors. Establishment of the ''angiogenesis dependence'' of solid tumor progression suggested that antiangiogenic gene therapy should be an important and potent procedure for limiting tumor growth and metastasis without significant side effects. 13 A gene therapy target cell should be easy to obtain and culture, and should survive in the body for a long time. Hematopoietic cells are attractive targets for gene therapy because their potential to generate a large population of progeny cells with new genetic material has been demonstrated. As evidenced by a number of recent studies, gene transfer into hematopoietic cells has rapidly become a focus of research into the mechanisms and therapeutic options for a variety of inherited, infectious and neoplastic diseases. [17] [18] [19] [20] One of the approaches to modulate angiogenesis is the use of agents that specifically inhibit the growth of endothelial cell. Several molecules that exhibit inhibitory effects on endothelial cell growth were recently reported.
Treatment with their recombinant proteins such as angiostatin and endostatin demonstrated that tumor growth was inhibited. 21, 22 However, there are several limitations to the clinical use of recombinant protein treatment. First, the requirement of prolonged administration increases the treatment cost for patients. Second, the production of recombinant protein is difficult due to physical properties and variations in the purification procedure. Third, relatively large quantities present difficult manufacturing and economic considerations. Finally, there exists the challenge of the long-term storage of bioactive protein and cumbersome daily administration. Thus, an alternative strategy to obviate these problems is the gene therapeutic use to generate protein in vivo rather than delivering exogenous recombinant protein.
RI is a molecule that demonstrated antiangiogenic properties. Our studies and several other studies have demonstrated that administration of purified RI can inhibit the growth of mice solid tumors. 23 But one of the most discouraging obstacles arises from the fact that RI activity in serum cannot last for a long time. Recently, Rafael et al transfected the ri gene into B16 melanoma cells and demonstrated the antitumor effect of RI. 24 In this study, we chose hematopoietic cells that can express ri gene as long as they can survive in vivo as target cells for gene therapy. After implantation of hematopoietic Anti-tumor effect of RI gene therapy P Fu et al cells, they proliferate and differentiate in the bone marrow. They are then carried throughout the body, especially to the spleen, thymus, and liver for further maturation. So we selected the spleen, thymus, and liver as detection tissues of ri expression. The distribution of the ri-modified cells was analyzed by RT-PCR. Different tissues showed different efficacies. Bone marrow had the highest efficiency of expression. The expression efficiency in spleen tissue was 40%, thymus tissue was 38%, and liver tissue was 20%. In contrast to Western blot, although the expression ratio of all liver samples was the lowest, the expression amount in the liver was high. The discrepancy may be due to the high number of provirus copy in hepatic cells or the relatively high activity in protein synthesis in the liver than the other tissues. Immunofluorescence confirmed that the ri gene could be efficiently expressed in bone marrow and peripheral blood. In animal studies, treatment of ri gene resulted in the inhibition of the tumor growth and prolongation of survival compared with the control groups, including the untransplanted group, uninfected group, and empty vector-virus infected group. In addition, increased apoptotic cells were found within the tumor tissues from the mice treated with the ri gene. Pathological and immunohistochemical study were conducted to assess the differences in vascularization between the ri-treated group and controls. The reduction of microvessel density was observed in tumors from the ri-treated group, whereas no difference in microvessel density was observed in tumors among the control groups. Thus, our results correlate decreased microvessel density in histological sections to slow growth speed of tumors.
So far, many angiogenesis inhibitors were found. They all possess the capacity to inhibit the formation of blood vessel via different mechanisms. And many studies demonstrated the efficacy of cancer gene therapy through the angiogenetic pathway. Most of them adapted one gene to inhibit angiogenesis. But angiogenesis is a rather complicated process, maybe two or more genes used together would be more effective. Although antiangiogenesis studies on animal showed positive results, it is still a long way from applying it to clinical therapeutic.
It can be concluded from our present study that cancer gene therapy using hematopoietic cells is a promising approach. Exogenous ri gene can be effectively expressed in hematopoietic cells and can be delivered throughout many tissues. Expressed RI effectively inhibits systemic angiogenesis and tumor growth in murine models. The findings in the present study may be of importance for the further exploration of the application of RI in the treatment of cancer. Anti-tumor effect of RI gene therapy P Fu et al
